Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 341 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nasopharyngeal Clear all
Enrolling by invitation Not applicable Interventional

Long-term Evaluation of Nasopharyngeal Airway in Hypotonia

NCT06614582
View directory record Official record
Conditions
Hypotonia, Muscle, Obstructive Sleep Apnea, Nasal Airway Obstruction
Interventions
Self-Supporting Nasopharyngeal Airway (ssNPA)
Device
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 23 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

NCT04367740
View directory record Official record
Conditions
Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2, Coronaviridae Infections, RNA Virus Infections, Virus Diseases, Communicable Disease
Interventions
To assess for development of IgG antibodies against SARS-CoV2
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
6,313 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1 Interventional

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

NCT00045006
View directory record Official record
Conditions
Cancer
Interventions
vorinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Zinc Supplements in Lowering Cadmium Levels in Smokers

NCT00376987
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
zinc oxide
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 120 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 4 Interventional

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

NCT06457503
View directory record Official record
Conditions
Nasopharyngeal Cancer Recurrent
Interventions
Toripalimab, Cisplatin, Gemcitabine, Carboplatin
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Irvine, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

NCT00248560
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
docetaxel, Gemcitabine
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00656513
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
Pilocarpine, ALTENS
Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
16
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

Self-sampling for the Study of COVID-19

NCT04447495
View directory record Official record
Conditions
Coronavirus
Interventions
iAMP test
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New Berlin, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Results available

Study Utilizing BIOZEK COVID-19 Antigen Rapid Test

NCT04926779
View directory record Official record
Conditions
Covid-19 Testing
Interventions
Biozek Covid-19 Antigen Rapid Test (Saliva)
Diagnostic Test
Lead sponsor
Mach-E B.V.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Flushing, New York • Southampton, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated No phase listed Observational

Nasopharyngeal Pressure Measurement During Neonatal Nasal Respiratory Support

NCT00766194
View directory record Official record
Conditions
Nasopharyngeal Airway Pressure
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 72 Hours
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

Predicting Outcomes for Covid-19 Using Sonography

NCT04384055
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral
Interventions
Lung Ultrasound
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting No phase listed Observational

Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors

NCT05733091
View directory record Official record
Conditions
Tumors
Interventions
Standard of Care
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1 Interventional

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

NCT00629226
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, bortezomib, cisplatin, intensity-modulated radiation therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2011 · Synced Oct 2, 2026, 4:11 AM EDT
Active, not recruiting Phase 2 Interventional

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

NCT04925544
View directory record Official record
Conditions
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma
Interventions
VK-2019
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study to Evaluate MEDI4736

NCT01693562
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI4736
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
47
States / cities
Scottsdale, Arizona • Burbank, California • Gilroy, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction

NCT01974726
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
ET Stress test, Sonotubometry, Forced Response Test (FRT), Inflation Deflation Test (IDT), Maneuver Sequence, 9-Step Test, Tubomanometry, Videoendoscopic assessment of ETF, Pressure chamber ET test
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
3 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

NCT06817889
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
Interventions
Remdesivir, Survey Administration, Biospecimen Collection, Nasal Swab
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Duarte, California • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Not applicable Interventional

Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia

NCT05527652
View directory record Official record
Conditions
Obstructive Sleep Apnea, Hypertonia, Muscle, Nasal Airway Obstruction, Tolerance, Trisomy 21, Down Syndrome
Interventions
Self-Supporting Nasopharyngeal Airway (ssNPA)
Device
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2

NCT06848309
View directory record Official record
Conditions
Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
Interventions
Bronchoscopy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional

Impact of Rapid Flu Testing in BMC ED

NCT02979730
View directory record Official record
Conditions
Influenza-Like Illness, Influenza
Interventions
Core Lab Test, ED Point of Care Test
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Self-Supporting Nasopharyngeal Airway in Hypotonia

NCT04846400
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Hypotonia, Child, Only
Interventions
ssNPA
Device
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

NCT00834093
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Epstein-Barr Virus Specific Immunotherapy
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 2, 2026, 4:11 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04974398
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Penpulimab, placebo
Drug
Lead sponsor
Akeso
Industry
Eligibility
12 Years to 75 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 2, 2026, 4:11 AM EDT